Agilon Health (NYSE:AGL) Given New $35.00 Price Target at Robert W. Baird

Agilon Health (NYSE:AGL) had its target price upped by Robert W. Baird from $20.00 to $35.00 in a report issued on Thursday,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Several other brokerages have also recently weighed in on AGL. Citigroup lowered their price target on shares of Agilon Health from $21.25 to $18.75 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. Benchmark boosted their price objective on shares of Agilon Health to $13.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Agilon Health from a “hold” rating to a “buy” rating and boosted their price objective for the company from $33.00 to $49.00 in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agilon Health in a research note on Monday, April 20th. Finally, Jefferies Financial Group raised Agilon Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $27.50 to $48.00 in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $34.48.

Agilon Health Price Performance

Agilon Health stock opened at $60.35 on Thursday. The company’s fifty day moving average price is $18.83 and its 200 day moving average price is $18.25. Agilon Health has a 1 year low of $7.48 and a 1 year high of $85.00. The stock has a market capitalization of $1.01 billion, a P/E ratio of -2.80 and a beta of 2.29. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02.

Agilon Health (NYSE:AGL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.76. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 133.13%. As a group, equities research analysts anticipate that Agilon Health will post -6.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Large investors have recently modified their holdings of the company. North Peak Capital Management LLC raised its stake in shares of Agilon Health by 10.8% during the fourth quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock worth $26,267,000 after purchasing an additional 3,715,460 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Agilon Health by 196.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock worth $13,812,000 after purchasing an additional 13,283,930 shares during the last quarter. CenterBook Partners LP raised its stake in shares of Agilon Health by 492.4% during the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after purchasing an additional 9,499,012 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Agilon Health by 1,346.6% during the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after purchasing an additional 9,505,837 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Agilon Health by 30.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company’s stock worth $5,523,000 after purchasing an additional 1,893,434 shares during the last quarter.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q1 results: Agilon reported EPS of $1.80 vs. consensus ~$1.04 and revenue above estimates; management raised FY?2026 revenue, medical margin and Adjusted EBITDA guidance — the core driver of today’s rally. agilon health Reports First Quarter 2026 Results
• Positive Sentiment: Operational progress: Company initiatives (cost control, care management) are beginning to show, supporting improved medical margin and profit metrics cited by management and analysts. This narrative is being highlighted in coverage and helped lift sentiment. Agilon Health Operational Initiatives Begin Showing Results
• Neutral Sentiment: Market commentary: Coverage explains why the stock is having a massive one?day move (earnings + guidance + short interest/liquidity dynamics), useful context but not new fundamental info. Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
• Neutral Sentiment: Broader market tailwind: Agilon’s move is also being picked up in midday market pieces covering health?care/AI/biologics rallies — helps momentum but is not company?specific. Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge
• Neutral Sentiment: Analyst moves: Robert W. Baird raised its price target (to $35) but left a neutral rating — a lift to price target consensus but still signals lingering analyst caution. Benzinga
• Negative Sentiment: Remaining concerns and downgrades: Some shops (reported via media) remain cautious — J.P. Morgan has downgraded the name previously, and the company still has a history of 2025 underperformance and suspended guidance last year, which keeps risk elevated even after today’s beat. JP Morgan downgrades Agilon Health (AGL)

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.